AntÃ³nio Almeida

List of Publications by Year
in descending order

44 papers	1,161 citations	471061 17 h-index	377514 34 g-index
45 all docs	45 docs citations	45 times ranked	1544 citing authors

#	Article	IF	Citations
1	Impact of somatic mutations on response to lenalidomide in lower-risk non-del(5q) myelodysplastic syndromes patients. Leukemia, 2021, 35, 897-900.	3.3	12
2	American Society of Hematology 2020 Podcast Collection: MDS and AML. Advances in Therapy, 2021, 38, 31-35.	1.3	0
3	Achievement of red blood cell transfusion independence in red blood cell transfusion-dependent patients with lower-risk non-del(5q) myelodysplastic syndromes correlates with serum erythropoietin levels. Leukemia and Lymphoma, 2020, 61, 1475-1483.	0.6	4
4	Vorinostat synergizes with antioxidant therapy to target myeloproliferative neoplasms. Experimental Hematology, 2019, 72, 60-71.e11.	0.2	6
5	Clinical Benefit-Risk Profile of Lenalidomide in Patients With Lower-risk Myelodysplastic Syndromes Without del(5q): Results of a PhaseÂIIIÂTrial. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 213-219.e4.	0.2	3
6	Treatment of Anemia in Transfusion-Dependent and Non-Transfusion-Dependent Lower-Risk MDS: Current and Emerging Strategies. HemaSphere, 2019, 3, e314.	1.2	21
7	Safety profile of lenalidomide in patients with lower-risk myelodysplastic syndromes without del(5q): results of a phase 3 trial. Leukemia and Lymphoma, 2018, 59, 2135-2143.	0.6	5
8	The Effect of Lenalidomide on Health-Related Quality of Life in Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes: Results From the MDS-005 Study. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 136-144.e7.	0.2	15
9	Considerations for Treatment-free Remission in Patients With Chronic Myeloid Leukemia: A Joint Patientâ€“Physician Perspective. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 375-379.	0.2	16
10	Hematology traning in Europe. International Journal of Laboratory Hematology, 2018, 40, 137-138.	0.7	0
11	Should more MDS patients be treated with immune-suppression?. Leukemia Research, 2018, 71, 25-26.	0.4	0
12	Clinical outcomes of AML patients treated with Azacitidine in Portugal: A retrospective multicenter study. Leukemia Research Reports, 2017, 7, 6-10.	0.2	4
13	Clinical benefit of eculizumab in patients with no transfusion history in the International Paroxysmal Nocturnal Haemoglobinuria Registry. Internal Medicine Journal, 2017, 47, 1026-1034.	0.5	19
14	Recent advances in the treatment of lower-risk non-del(5q) myelodysplastic syndromes (MDS). Leukemia Research, 2017, 52, 50-57.	0.4	25
15	Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study. International Journal of Molecular Sciences, 2017, 18, 837.	1.8	19
16	Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia. Future Oncology, 2016, 12, 293-302.	1.1	36
17	Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents. Journal of Clinical Oncology, 2016, 34, 2988-2996.	0.8	190
18	Design and rationale of the QUAZAR Lower-Risk MDS (AZA-MDS-003) trial: a randomized phase 3 study of CC-486 (oral azacitidine) plus best supportive care vs placebo plus best supportive care in patients with IPSS lower-risk myelodysplastic syndromes and poor prognosis due to red blood cell transfusionâ€“dependent anemia and thrombocytopenia. BMC Hematology, 2016, 16, 12.	2.6	31

#	Article	IF	Citations
19	Cessation of Tyrosine Kinase Inhibitors Treatment in Chronic Myeloid Leukemia Patients with Deep Molecular Response: Results of the Euro-Ski Trial. Blood, 2016, 128, 787-787.	0.6	43
20	The Bone Marrow-Mediated Protection of Myeloproliferative Neoplastic Cells to Vorinostat and Ruxolitinib Relies on the Activation of JNK and PI3K Signalling Pathways. PLoS ONE, 2015, 10, e0143897.	1.1	13
21	Safety of Lenalidomide (LEN) 10mg in Non-Del(5q) Versus Del(5q) in the Treatment of Patients (Pts) with Lower-Risk Myelodysplastic Syndromes (MDS): Pooled Analysis of Treatment-Emergent Adverse Events (TEAEs). Blood, 2015, 126, 2880-2880.	0.6	1
22	Epigenetic Alterations in Fanconi Anaemia: Role in Pathophysiology and Therapeutic Potential. PLoS ONE, 2015, 10, e0139740.	1.1	8
23	Optimizing treatments in rare diseases: Will our evidence come from registry data?. Leukemia Research, 2014, 38, 421-422.	0.4	1
24	Survey of professional competence in hematology in Europe. Haematologica, 2014, 99, 404-408.	1.7	2
25	Efficacy and Safety of Lenalidomide (LEN) Versus Placebo (PBO) in RBC-Transfusion Dependent (TD) Patients (Pts) with IPSS Low/Intermediate (Int-1)-Risk Myelodysplastic Syndromes (MDS) without Del(5q) and Unresponsive or Refractory to Erythropoiesis-Stimulating Agents (ESAs): Results from a Randomized Phase 3 Study (CC-5013-MDS-005). Blood, 2014, 124, 409-409.	0.6	11
26	Efficacy and tolerability of 5-day azacytidine dose-intensified regimen in higher-risk MDS. Annals of Hematology, 2013, 92, 1201-1206.	0.8	12
27	Treatment of acute erythroleukemia with Azacitidine: A case series. Leukemia Research Reports, 2013, 2, 41-43.	0.2	4
28	Modifying disease in CMML: Who responds to Azacitidine?. Leukemia Research, 2013, 37, 603-604.	0.4	1
29	Vorinostat Induces Apoptosis and Differentiation in Myeloid Malignancies: Genetic and Molecular Mechanisms. PLoS ONE, 2013, 8, e53766.	1.1	54
30	Generalized skin reactions in patients with MDS and CMML treated with azacitidine: Effective management with concomitant prednisolone. Leukemia Research, 2012, 36, e211-e213.	0.4	11
31	Treatment of chronic myelomonocytic leukemia with 5-Azacitidine: A case series and literature review. Leukemia Research, 2012, 36, 1071-1073.	0.4	52
32	Inherited glycosylphosphatidyl inositol deficiency: A treatable CDG. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2009, 1792, 874-880.	1.8	32
33	Chapter 16 Inherited GPI Deficiency. The Enzymes, 2009, 26, 357-373.	0.7	0
34	Regulation of hematopoiesis in vitro and in vivo by invariant NKT cells. Blood, 2006, 107, 3138-3144.	0.6	33
35	Bone involvement in sickle cell disease. British Journal of Haematology, 2005, 129, 482-490.	1.2	321
36	Regulation of Hematopoiesis In Vitro and In Vivo by Invariant NKT Cells.. Blood, 2005, 106, 2277-2277.	0.6	0

#	Article	IF	Citations
37	Automated computer result reporting for haemoglobinopathy screening. International Journal of Laboratory Hematology, 2004, 26, 21-24.	0.2	2
38	Evidence That Human NKT Cells Enhance Haemopoiesis through Recognition of CD1d Expressed in Haemopoietic Stem Cells with Long Term Clonogenic Capacity.. Blood, 2004, 104, 4129-4129.	0.6	4
39	Depletion of the CD1d-Restricted NKT Cells Suppresses In Vitro Alloreactivity: A Possible Means To Prevent aGVHD.. Blood, 2004, 104, 3069-3069.	0.6	0
40	Therapeutic challenges in childhood sickle cell disease Part 1: current and future treatment options. British Journal of Haematology, 2003, 120, 725-736.	1.2	42
41	Therapeutic challenges in childhood sickle cell disease Part 2: a problem-orientated approach. British Journal of Haematology, 2003, 120, 737-743.	1.2	25
42	Thromboprophylaxis with unmonitored intermediate-dose low molecular weight heparin in pregnancies with a previous arterial or venous thrombotic event. Blood Coagulation and Fibrinolysis, 2003, 14, 735-739.	0.5	28
43	Unusual presentation of factor XIII deficiency. Haemophilia, 2002, 8, 703-705.	1.0	16
44	Fludarabine-based stem cell transplantation protocol for Fanconi's anaemia in myelodysplastic transformation. British Journal of Haematology, 2001, 112, 427-429.	1.2	22